For the pharma industry, the Bristol Myers Squibb is moving part of its drug safety monitoring operations to India in ann unprecedented move. With the outsourcing solutions provider, the US based drug maker has teamed up with the outsourcing solution provider. Accenture to launch the industry’s first joint pharmacovigilance center that the US based drug maker has teamed up. The first time a collaboration for the end to end safety case processing has been established and it includes a specialisted activities including the medical review of any reported adverse reactions.
By more than 140 accenture employees that will undertake the processing and the coding of adverse event data and that the generation of the regulatory reports on the safety as well as physician medical review of adverse events, the new pharmacovigilance center will be operated. The team is organized as a parallel process and the extension of the BMS pharmacovigilance headquarters operations and it will allow for the seamless handling of the data and the reports between the Accenturre and BMS while not comprising patient safety. Working with the accenture, bristol myers, the squibb will continue to access world class talent to deliver on their regulatory obligations while enhancing their focus on the patient safety. The leading companies collaborative partnership with the the Bristol Myers Squibb they have established an industry leading operation that is delivering substantial efficiency and it improved flexibility for the Bristol Myers Squibb’s pharmacovigilance organization.
The part of the Accenture’s Life Sciences Centers of the Excellence in Bangalore and Chennai that BMS that is already utilizes. Part of the multi-year R&D deal inked in April, the new center furthers BMS efforts to significantly expand its research capabilities in India as an integral part of the company’s global strategy. The company recently announced that its recruiting plans and James Cornelius, the CEO of the pharma giant admitted that it would, it includes workforce reductions in some areas and the rationalization of some facilities. The challenge is to reduce costs while at the same time continue in investing in growth areas. With a promising R&D pipeline, they plan to invest in R&D and the business including specialty medicines and biologics where they see tremendous growth potential.
REFERENCE:
http://www.outsourcing-pharma.com/Clinical-Development/BMS-to-outsource-some-pharmacovigilance-operations-to-India?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
